ITOS
- iTeos Therapeutics, Inc.
()
Overview
Company Summary
iTeos Therapeutics, Inc. is a biotechnology company that focuses on developing innovative therapeutics to treat cancer. The company utilizes its expertise in immunology and molecular biology to target certain signaling pathways within the immune system, with the aim of unleashing the body's own immune response against cancer cells.
The core focus of iTeos Therapeutics is on developing small molecules and immunotherapies that address the complex mechanisms of immune suppression in the tumor microenvironment. By targeting immune checkpoint pathways and other key regulatory mechanisms, the company aims to enhance the body's immune response and enable effective anti-tumor activity.
iTeos Therapeutics has a portfolio of drug candidates at various stages of development, from preclinical to early-stage clinical trials. These candidates target specific immune checkpoint proteins, such as TIGIT and A2A receptor, which play important roles in regulating immune responses within tumors.
The company also collaborates with academic institutions, research organizations, and pharmaceutical companies to further advance its research and development efforts. By leveraging cutting-edge technologies, such as Next-Generation Sequencing and functional genomics, iTeos Therapeutics aims to identify novel targets and biomarkers that can be used to design personalized treatments for cancer patients.
Overall, iTeos Therapeutics is dedicated to advancing its pipeline of innovative cancer therapies that harness the power of the immune system to fight against cancer. Their goal is to make a significant impact in improving patient outcomes and ultimately changing the treatment paradigm for various types of cancers.